BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 12908351)

  • 1. [Meningitis due to Listeria monocytogenes as a complication of infliximab therapy].
    Joosten AA; van Olffen GH; Hageman G
    Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1470-2. PubMed ID: 12908351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Listeria meningitis in a patient with Crohn's disease--a seldom, but clinically relevant adverse event of therapy with infliximab].
    Dederichs F; Pinciu F; Gerhard H; Eveld K; Stallmach A
    Z Gastroenterol; 2006 Aug; 44(8):657-60. PubMed ID: 16902896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Listeria meningitis associated with infliximab.
    Bowie VL; Snella KA; Gopalachar AS; Bharadwaj P
    Ann Pharmacother; 2004 Jan; 38(1):58-61. PubMed ID: 14742795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Listeria meningitis complicating a patient with ulcerative colitis on concomitant infliximab and hydrocortisone.
    Parihar V; Maguire S; Shahin A; Ahmed Z; O'Sullivan M; Kennedy M; Smyth C; Farrell R
    Ir J Med Sci; 2016 Nov; 185(4):965-967. PubMed ID: 26358724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis.
    Bourikas LA; Kourbeti IS; Koutsopoulos AV; Koutroubakis IE
    Gut; 2008 Mar; 57(3):425; author reply 425-6. PubMed ID: 18268059
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease.
    Izbéki F; Nagy F; Szepes Z; Kiss I; Lonovics J; Molnár T
    Inflamm Bowel Dis; 2008 Mar; 14(3):429-31. PubMed ID: 17973302
    [No Abstract]   [Full Text] [Related]  

  • 7. How to improve the safety of biologic therapy in Crohn's disease.
    Ferkolj I
    J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area.
    Jain VV; Evans T; Peterson MW
    Respir Med; 2006 Jul; 100(7):1291-3. PubMed ID: 16545951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pneumocystis pneumonia during infliximab treatment for active Crohn's colitis].
    Minnee RC; Stokkers P; Riemens SC; Hommes DW
    Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2290-5. PubMed ID: 16240855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucormycosis in a Crohn's disease patient treated with infliximab.
    Wall GC; Leman BI
    Digestion; 2009; 80(3):182-4. PubMed ID: 19776582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
    Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB
    Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Listeria meningitis as complication of treatment with infliximab in a patient with Crohn's disease].
    Osuna Molina R; Ferrer Ríos T; Gallego Gallegos R; Ramos Lora M; Ynfante Ferrús M; Figueruela López B
    Rev Esp Enferm Dig; 2006 Jan; 98(1):60-1. PubMed ID: 16555939
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease.
    Vadikolias K; Kouklakis G; Heliopoulos I; Argyropoulou P; Papanas N; Tzilonidou M; Prassopoulos P; Piperidou H
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):159-62. PubMed ID: 17273002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
    Moiton MP; Richez C; Dumoulin C; Mehsen N; Dehais J; Schaeverbeke T
    Clin Microbiol Infect; 2006 Dec; 12(12):1151-3. PubMed ID: 17121619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of acute and necrotizing cutaneous Mycobacterium marinum infection in a patient treated with infliximab for Crohn's disease].
    Guyot A; Begon E; Abramowitz L; Landry J; Marinho E; Descamps V; Crickx B
    Ann Dermatol Venereol; 2009 Nov; 136(11):806-10. PubMed ID: 19917434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasiform and pustular eruption induced by infliximab.
    Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
    J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing the risks and benefits of prolonged use of infliximab.
    Schölmerich J
    Gut; 2009 Apr; 58(4):477-8. PubMed ID: 19299379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.